Lasofoxifene

Lasofoxifene is a selective estrogen receptor modulator (SERM) that is used in the treatment of osteoporosis and vaginal atrophy. It was developed by Pfizer Inc., a multinational pharmaceutical corporation.

Pharmacology

Lasofoxifene works by selectively binding to estrogen receptors in various tissues in the body. It acts as an agonist in some tissues and an antagonist in others. In the bones and the cardiovascular system, it acts as an agonist, thereby helping to maintain bone density and reduce the risk of cardiovascular disease. In the breasts and uterus, it acts as an antagonist, reducing the risk of cancer in these tissues.

Clinical Use

Lasofoxifene is primarily used in the treatment of postmenopausal osteoporosis. It helps to maintain bone density and reduce the risk of fractures. It is also used in the treatment of vaginal atrophy, a condition characterized by the thinning and inflammation of the vaginal walls due to a decrease in estrogen.

Side Effects

Like all medications, Lasofoxifene can cause side effects. Common side effects include hot flashes, leg cramps, and an increased risk of blood clots. Less common but more serious side effects include an increased risk of endometrial cancer and cardiovascular disease.

Development and Approval

Lasofoxifene was developed by Pfizer Inc. and was approved by the U.S. Food and Drug Administration (FDA) in 2009 for the treatment of postmenopausal osteoporosis and vaginal atrophy.

See Also

• Selective estrogen receptor modulator
• Osteoporosis
• Vaginal atrophy
• Pfizer